Don't Miss a Beat: CARDIO-TTRansform and New HF Guidelines at ESC 2026
Sep 23, 08:31 PM
Share
Subscribe
Recorded on-site at ESC Congress 2026 in Munich, Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, discuss a late-breaking trial in transthyretin amyloid cardiomyopathy and what has changed in the new European heart failure guidelines. The conversation focuses on how clinicians should interpret the latest evidence in day-to-day practice.
Read the full article: https://www.hcplive.com/view/don-t-miss-a-beat-cardio-ttransform-and-new-hf-guidelines-at-esc-2026
Stephen Greene, MD, is an advanced heart failure specialist at Duke University School of Medicine. Muthiah Vaduganathan, MD, MPH, is a cardiologist at Brigham and Women's Hospital.
References
- Fontana M, Masri A, Solomon SD, et al; CARDIO-TTRansform Investigators. Eplontersen for transthyretin amyloid cardiomyopathy. N Engl J Med. Published online August 28, 2026. doi:10.1056/NEJMoa2608510
- Gillmore JD, Hamatani Y, Fontana M, et al. Gene silencer therapy in transthyretin amyloid cardiomyopathy: a meta-analysis of outcomes trials. JAMA. Published online August 30, 2026. doi:10.1001/jama.2026.17246
- Køber L, Adamo M, Ruwald A, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;ehag100. doi:10.1093/eurheartj/ehag100